Paratek Pharmaceuticals PRTK Stock
Paratek Pharmaceuticals Price Chart
Paratek Pharmaceuticals PRTK Financial and Trading Overview
Paratek Pharmaceuticals stock price | 2.23 USD |
Previous Close | 2.19 USD |
Open | 2.18 USD |
Bid | 0 USD x 28000 |
Ask | 0 USD x 27000 |
Day's Range | 2.18 - 2.19 USD |
52 Week Range | 1.29 - 3.65 USD |
Volume | 459.85K USD |
Avg. Volume | 1.11M USD |
Market Cap | 125.45M USD |
Beta (5Y Monthly) | 1.584859 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | October 31, 2014 |
1y Target Est | 3.1 USD |
PRTK Valuation Measures
Enterprise Value | 339.99M USD |
Trailing P/E | N/A |
Forward P/E | -27.375002 |
PEG Ratio (5 yr expected) | 0.02 |
Price/Sales (ttm) | 0.752795 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 2.04 |
Enterprise Value/EBITDA | -7.097 |
Trading Information
Paratek Pharmaceuticals Stock Price History
Beta (5Y Monthly) | 1.584859 |
52-Week Change | 21.66% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3.65 USD |
52 Week Low | 1.29 USD |
50-Day Moving Average | 2.02 USD |
200-Day Moving Average | 2.21 USD |
PRTK Share Statistics
Avg. Volume (3 month) | 1.11M USD |
Avg. Daily Volume (10-Days) | 2.76M USD |
Shares Outstanding | 57.28M |
Float | 50.73M |
Short Ratio | 13.61 |
% Held by Insiders | 12.26% |
% Held by Institutions | 52.56% |
Shares Short | 4.36M |
Short % of Float | 9.24% |
Short % of Shares Outstanding | 7.62% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:12 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -39.48% |
Operating Margin (ttm) | -28.98% |
Gross Margin | 61.91% |
EBITDA Margin | -28.74% |
Management Effectiveness
Return on Assets (ttm) | -18.80% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 166.64M USD |
Revenue Per Share (ttm) | 3 USD |
Quarterly Revenue Growth (yoy) | 25.60% |
Gross Profit (ttm) | 99.39M USD |
EBITDA | -47908000 USD |
Net Income Avi to Common (ttm) | -65799000 USD |
Diluted EPS (ttm) | -1.17 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 45.03M USD |
Total Cash Per Share (mrq) | 0.79 USD |
Total Debt (mrq) | 259.57M USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 3.39 |
Book Value Per Share (mrq) | -3.3 |
Cash Flow Statement
Operating Cash Flow (ttm) | -35941000 USD |
Levered Free Cash Flow (ttm) | -36904624 USD |
Profile of Paratek Pharmaceuticals
Country | United States |
State | MA |
City | Boston |
Address | 75 Park Plaza |
ZIP | 02116 |
Phone | 617 807 6600 |
Website | https://www.paratekpharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 268 |
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.
Q&A For Paratek Pharmaceuticals Stock
What is a current PRTK stock price?
Paratek Pharmaceuticals PRTK stock price today per share is 2.23 USD.
How to purchase Paratek Pharmaceuticals stock?
You can buy PRTK shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Paratek Pharmaceuticals?
The stock symbol or ticker of Paratek Pharmaceuticals is PRTK.
Which industry does the Paratek Pharmaceuticals company belong to?
The Paratek Pharmaceuticals industry is Biotechnology.
How many shares does Paratek Pharmaceuticals have in circulation?
The max supply of Paratek Pharmaceuticals shares is 57.32M.
What is Paratek Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Paratek Pharmaceuticals PE Ratio is 0.00000000 now.
What was Paratek Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Paratek Pharmaceuticals EPS is 0 USD over the trailing 12 months.
Which sector does the Paratek Pharmaceuticals company belong to?
The Paratek Pharmaceuticals sector is Healthcare.
Paratek Pharmaceuticals PRTK included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}